Psoriasis
https://en.wikipedia.org/wiki/Psoriasis
☆ AI Dermatology — Free ServiceKatika matokeo ya 2022 ya Stiftung Warentest kutoka Ujerumani, kuridhika kwa watumiaji na ModelDerm kulikuwa chini kidogo kuliko na mashauriano ya matibabu ya simu yanayolipishwa. relevance score : -100.0%
References
Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Matibabu mbalimbali yanaweza kusaidia kudhibiti dalili. Matibabu haya ni pamoja na krimu za steroid, krimu ya vitamini D3, mwanga wa urujua, na dawa za kupunguza kinga mwilini, kama vile methotrexate. Takriban 75 % ya wagonjwa wa ngozi hubona maboresho kwa kutumia krimu pekee. Dawa mbalimbali za kibaolojia zinatengenezwa kwa ajili ya matibabu ya psoriasis.
Psoriasis ni ugonjwa wa kawaida unaowathiri 2‑4 % ya watu. Wanaume na wanawake huathiriwa kwa viwango sawa. Ugonjwa huo unaweza kuanza katika umri wowote, lakini kawaida huanza katika watu wazima. Psoriatic arthritis huathiri hadi 30 % ya watu wenye psoriasis.
○ Matibabu - Dawa za OTC
Mwangaza wa jua unaweza kusaidia psoriasis kwa sababu mionzi ya jua husababisha mabadiliko ya kinga katika wagonjwa wenye psoriasis. Mafuta ya hydrocortisone kidogo yanaweza kusaidia kutibu vidonda vidogo vya psoriasis.
#OTC steroid ointment
○ Matibabu
Psoriasis ni ugonjwa sugu na madawa mengi ya matibabu yanapatikana. Dawa za kibaolojia ni bora zaidi lakini ni ghali sana.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)